Skip to content
DataLookout
Menu

POETYK-PsO-PedNCT06979453

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 23 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 132 → 137 locations
  2. Notable Eligibility criteria expanded, about 15 words
    • Study sites: 132 to 133
    • Secondary endpoints: details revised at 2 of 18 entries
  3. Minor Study sites revised (132)v22
  4. Minor Trial sites expanded: 129 → 132 locationsv21
  5. Minor Study sites: 127 to 129v20
  6. Minor Trial sites expanded: 123 → 127 locationsv19
  7. Minor Trial sites expanded: 120 → 123 locationsv18
  8. Minor Trial sites expanded: 116 → 120 locationsv17
  9. Minor Study sites: 114 to 116v16
  10. Minor Study sites revised (114)v15
  11. Minor Study sites: 111 to 114v14
  12. Minor Study sites: 100 to 111v12
  13. Minor Study sites: 98 to 100v11
  14. Minor Study sites: 95 to 98
    • Start date changed from estimate of Nov 15, 2025 to Dec 3, 2025
    v10
  15. Minor Study sites: 92 to 95
    • Start date: Oct 25, 2025 to Nov 15, 2025
    v9
  16. Notable Start date: Sep 25, 2025 to Oct 25, 2025
    • Study sites: 86 to 92
    v8
  17. Notable Start date: Aug 26, 2025 to Sep 25, 2025
    • Study sites: 81 to 86
    v7
  18. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 71 to 81
    v6
  19. Minor Study sites: 70 to 71v5
  20. Minor Study sites: 65 to 70v4
  21. Minor Study sites: 61 to 65v3
  22. Minor Study sites: 58 to 61v2
  23. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)
Timeframe: At week 16
Number of participants achieving a static Physicians Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline
Timeframe: At week 16

Secondary (18)

Number of participants achieving at least 90% improvement in PASI (PASI 90)
Change from baseline in PASI
Change from baseline in body surface area (BSA) involvement
Change from baseline in worst itch numeric rating scale (WI-NRS)
Number of participants achieving ≥ 4 improvement from baseline in the WI-NRS score (in participants with baseline score ≥ 4)
Show 13 moreShow less
Change from baseline in Children's Dermatology Life Quality Index (CDLQI) score
Number of participants achieving CDLQI 0/1 (among participants with a baseline CDLQI score ≥ 2)
Number of participants with treatment emergent adverse events
Number of participants with serious adverse events
Number of participants with clinically significant changes in laboratory parameters
Number of participants with clinically significant changes in physical examinations
Number of participants with clinically significant changes in vital signs
Number of participants with protective titers of antibodies to measles
Number of participants with protective titers of antibodies to tetanus
Number of participants with protective titers of antibodies to pertussis
Body weight
Height
Sexual maturation

Arms and interventions

Administration of DeucravacitinibActive comparator
PlaceboPlacebo comparator

Drugs: Deucravacitinib

Other: Placebo

Sites

137 sites in 16 countries

United States 47, China 11, Poland 10, Argentina 8, Canada 8, Romania 8, Brazil 7, Mexico 7, Germany 5, Spain 5, Taiwan 5, Belgium 4, Colombia 4, Hungary 3, Puerto Rico 3, Italy 2